In the previous article, we discussed the effects of Highly Bioavailable Curcumin-Theracurmin on "preventing dementia" and its "protective effects on patients with existing dementia or mild cognitive impairment."
This time, we will explore the various clinical benefits of Theracurmin.
The following are medical papers found using Theracurmin as the keyword in PubMed (a global medical literature search engine).
Dr. Huang has categorized them based on different types.
I. Human Trials Evidence
a. Knee Joint Cartilage Protection
"The Oral Administration of Highly-Bioavailable Curcumin for One Year Has Clinical and Chondro-Protective Effects: A Randomized, Double-Blinded, Placebo-Controlled Prospective Study"
Arthrosc Sports Med Rehabil. 2022 Jan 13;4(2):e393-e402 (IF:1.66)
Randomized controlled trial:
43 patients over 20 years old undergoing knee joint surgery due to joint disease.
Experimental group (n=23) received 180mg Theracurmin® daily, and placebo group (n=20) continued for 12 months.
Evaluation included the Japanese Orthopaedic Association Knee Osteoarthritis Score (JOA), Visual Analog Scale (VAS), and Japanese Knee Osteoarthritis Measure (JKOM) as clinical symptoms.
T2 mapping on magnetic resonance imaging was used as an indicator of cartilage protection.
Intraoperative ultrasound evaluation of joint cartilage was performed as a standard for measuring cartilage protection.
Results:
No significant differences were observed between the experimental and placebo groups in JOA, VAS, JKOM values, and T2 mapping.
However, during the second arthroscopic examination, the experimental group showed significantly better cartilage stiffness and surface roughness than the placebo group.
Conclusion:
Compared to the placebo, oral administration of Theracurmin® for one year demonstrated significantly better cartilage protection without worse clinical effects or adverse events.
b. Knee Osteoarthritis
"The Efficacy and Safety of Highly-Bioavailable Curcumin for Treating Knee Osteoarthritis: A 6-Month Open-Labeled Prospective Study"
Clin Med Insights Arthritis Musculoskelet Disord. 2020 Aug 12:13:1179544120948471 (IF:2.6)
Open-label prospective study:
Selected 50 patients over 40 years old with Kellgren-Lawrence II, III, or IV grade knee osteoarthritis.
Received 180 mg Theracurmin daily for 6 months.
Patients were assessed for knee joint symptoms (JOA, VAS, JKOM) at 0, 1, 2, 3, 4, 5, and 6 months.
Results:
During the study period, 5 participants dropped out, but none due to major issues.
No significant adverse effects were observed with Theracurmin treatment.
Effective group: 34 cases (75.6%), ineffective group: 11 cases.
Conclusion:
This study demonstrated the safety and efficacy of Theracurmin® in treating various types of knee osteoarthritis. Theracurmin shows significant potential in treating human knee osteoarthritis.
c. Short-term Effects on Knee Osteoarthritis
"Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study"
J Orthop Sci. 2014 Nov;19(6):933-9 (IF:1.805)
Randomized, double-blind, placebo-controlled trial:
50 cases of Kellgren-Lawrence II or III grade knee osteoarthritis patients over 40 years old were included in this prospective clinical study.
Received 180mg Theracurmin® or placebo daily for 8 weeks.
Patients were assessed for knee joint symptoms using JOA, VAS, and JKOM scoring systems at 0, 2, 4, 6, and 8 weeks.
Evaluation included the need for knee joint replacement surgery and NSAIDS usage.
Results:
After 8 weeks of treatment, the Theracurmin group showed significantly lower knee pain VAS scores compared to the placebo group.
Theracurmin was more effective in reducing dependence on celecoxib, but no significant adverse effects were observed.
Conclusion:
Theracurmin® demonstrates potential in treating human knee osteoarthritis.
d. Muscle Damage
"Attenuation of indirect markers of eccentric exercise-induced muscle damage by curcumin"
Eur J Appl Physiol. 2015 Sep;115(9):1949-57 (IF:3.346)
Randomized controlled trial:
14 young men (24 ± 1 years) performed 50 maximal eccentric contractions of the elbow flexors.
Received 150 mg Theracurmin® or placebo 12 hours before and after each exercise.
The Theracurmin group showed smaller decreases in maximum voluntary contraction (MVC) torque and smaller peaks in serum CK activity.
Conclusion:
Theracurmin® intake can alleviate muscle damage.
e. Crohn's Disease
"Highly Bioavailable Curcumin Derivative Ameliorates Crohn‘s Disease Symptoms: A Randomized, Double-Blind, Multicenter Study"
J Crohns Colitis. 2020 Dec 2;14(12):1693-1701 (IF:8.0)
Randomized controlled trial:
Conducted a randomized, double-blind study in five independent medical centers in Japan.
Patients with mild to moderate Crohn's disease took Theracurmin® (360mg/day, n=20) or placebo (n=10) for 12 weeks.
The experimental group showed a significant decrease in clinical disease activity at week 12, a reduction in endoscopic severity, and significant healing of anal lesions.
Conclusion:
Theracurmin® exhibits significant clinical and endoscopic efficacy and good safety in patients with mild to moderate Crohn's disease.
f. Common Cold
"Effects of Highly Bioavailable Curcumin Supplementation on Common Cold Symptoms and Immune and Inflammatory Functions in Healthy Japanese Subjects: A Randomized Controlled Study"
J Diet Suppl. 2024;21(1):71-98 (IF:0.442)
Randomized controlled trial:
A randomized, double-blind, placebo-controlled study was conducted on 99 healthy Japanese adults for 12 weeks.
Participants were divided into three groups: TS-P1 (Theracurmin Super [TS-P1], 150 mg/day), CR-033P (Theracurmin [CR-033P], 150 mg/day), and placebo (each group n=33).
Results:
The cumulative days of persistent common cold symptoms were significantly lower in the TS-P1 and CR-033P groups (both Theracurmin groups) compared to the placebo group. No adverse reactions were observed.
g. Stabilize Oxidized Low-Density Lipoprotein (AT-LDL)
"Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus"
J Diabetes Res. 2019 Nov 23:2019:8208237 (IF:4.016)
Randomized controlled trial:
Patients with Impaired Glucose Tolerance and Diabetes Mellitus:
Theracurmin® demonstrated no significant difference in HbA1C levels but significantly stabilized α1-antitrypsin-low-density lipoprotein (AT-LDL) levels compared to the placebo group.
Mild COPD:
"Highly Absorptive Curcumin Reduces Serum Atherosclerotic Low-Density Lipoprotein Levels in Patients with Mild COPD"
Int J Chron Obstruct Pulmon Dis. 2016 Aug 26:11:2029-34 (IF:3.157)
Theracurmin® resulted in a significant lower percent change in AT-LDL levels in patients with mild COPD, suggesting a potential preventive effect on cardiovascular events.
h. Chemobrain Improvement
Title: "The Effect of Theracurmin on Cognitive Function in an Older Patient with Chemobrain"
Clin Interv Aging. 2020 May 19:15:691-693 (IF:3.829)
A case report demonstrated cognitive improvement in a 76-year-old breast cancer patient with chemobrain after three months of Theracurmin® treatment.
II. Animal Experiments:
a. Fatty Liver:
Title: "Theracurmin Prevents High Fat Diet-Induced Hepatic Steatosis Development in Mice"
Toxicol Res. 2019 Oct;35(4):403-410 (IF:2.68)
Theracurmin® significantly reduced triglyceride levels and prevented hepatic fat accumulation induced by a high-fat diet in mice.
b. Hearing Loss Prevention:
Title: "Preventive Effect of Curcumin on Hearing Loss Induced by Noise in Mice"
J Pharmacol Sci. 2017 Aug;134(4):225-233 (IF:3.578)
Theracurmin® demonstrated a strong preventive effect against hearing loss induced by repeated exposure to noise in mice.
c. Parasitic Infection:
Title: "Protective Effects of Theracurmin Treatment during Trypanosoma cruzi Infection in Mice"
Front Cell Infect Microbiol. 2023 Mar 24:13:1143360 (IF:5.7)
Theracurmin® showed protective effects on testicular function in mice infected with Trypanosoma cruzi.
d. Osteoarthritis:
Title: "Highly Bioavailable Curcumin Suppresses Articular Cartilage Damage in Rats with Osteoarthritis"
Food Sci Biotechnol. 2019 Oct 5;29(2):251-263. (IF:3.231)
Theracurmin® significantly improved weight distribution and reduced markers of cartilage damage in rats with osteoarthritis.
e. Inflammatory Bowel Disease (IBD):
Title: "Nanoparticle Curcumin Ameliorates Experimental Colitis in Mice"
PLoS One. 2017 Oct 6;12(10):e0185999 (IF: 3.752)
Theracurmin® improved various parameters in mice with colitis, indicating its potential as a treatment for IBD.
f. Familial Adenomatous Polyposis (FAP):
Title: "Theracurmin Inhibits Intestinal Polyp Development in Apc-Mutant Mice"
Cancer Sci. 2020 Apr;111(4):1367-1374 (IF: 6.518)
Theracurmin® inhibited intestinal polyp development in Apc-mutant mice, suggesting an anti-inflammatory effect.
g. Brain Injury:
Title: "Potential Protective Effect of Highly Bioavailable Curcumin on Oxidative Stress in Mice Brain"
Food Funct. 2014 May;5(5):984-9 (IF:6.317)
Theracurmin® demonstrated protective effects against oxidative stress-induced brain damage in mice.
III. Cellular Experiments:
a. Esophageal Squamous Cell Carcinoma:
Title: "Combination Treatment with Highly Bioavailable Curcumin Exhibits Antitumor Effects on Esophageal Squamous Cell Carcinoma"
J Gastroenterol. 2019 Aug;54(8):687-698 (IF: 6.772)
Theracurmin demonstrated cytotoxic effects on esophageal squamous cell carcinoma cells and enhanced antitumor activity when combined with an NQO1 inhibitor.
b. Esophageal Adenocarcinoma:
Title: "Nano-Curcumin Inhibits Proliferation of Esophageal Adenocarcinoma Cells"
Front Oncol. 2013 May 29:3:137 (IF:5.738)
Theracurmin® significantly reduced the proliferation of esophageal adenocarcinoma cells without affecting normal esophageal cells.
c. Prostate and Bladder Cancer:
Title: "Theracurmin Efficiently Inhibits the Growth of Human Prostate and Bladder Cancer Cells"
Oncol Rep. 2016 Mar;35(3):1463-72 (IF: 4.2)
Theracurmin® induced apoptotic cell death and cell cycle disruption, showing potential as a supplementary anticancer agent.
The above are the globally published research results on high bioavailability curcumin, Theracurmin.
In fact, curcumin has many clinical applications.
The following list highlights proven effective outcomes of general curcumin from a review study [Curcumin: Biological Activities and Modern Pharmaceutical Forms. Antibiotics (Basel) 2022 Jan 20;11(2):135]:
Finally, the paper includes images summarizing the various benefits of curcumin.
